NCT05774145

Brief Summary

The aim is to compare sedation using dexmedetomidine to sedation -free approach in management of agitated COPD patients receiving NIV

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2023

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 22, 2023

Completed
7 days until next milestone

Study Start

First participant enrolled

March 1, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

March 17, 2023

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

March 17, 2023

Status Verified

March 1, 2023

Enrollment Period

2.8 years

First QC Date

February 22, 2023

Last Update Submit

March 15, 2023

Conditions

COPD

Outcome Measures

Primary Outcomes (1)

  • precedex on COPD irritable on non invasive machine

    control of Agitation by RASS

    3/2023_3/2025

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

observational study

You may not qualify if:

  • cardiac dysfunction
  • Hepatic dysfunction
  • Haemodynamic instability

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle investigator

Study Record Dates

First Submitted

February 22, 2023

First Posted

March 17, 2023

Study Start

March 1, 2023

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

March 17, 2023

Record last verified: 2023-03